Clinical Study

Pediatric Neurocysticercosis: Usefulness of Antibody Response in Cysticidal Treatment Follow-Up

Figure 2

ELISA percent seropositivity in (a) NCC children before the treatment with albendazole, 3–6 months and 12 months after treatment. (b) NCC treatment nonresponders at 3–6 months and 12 months after treatment. (c) NCC treatment responders at 3–6 months and 12 months after treatment.
904046.fig.002a
(a)
904046.fig.002b
(b)
904046.fig.002c
(c)